Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?

Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?

The anti-CD52 (Campath-1) monoclonal antibodies (Mabs) have a substantial history of use for controlling graft-versus-host disease in allogeneic bone marrow transplantation. Now, with the availability of a humanised form, alemtuzumab (Campath-1H), and the demonstration that this agent can reduce the...

Bibliográfalaš dieđut
Váldodahkkit:	Hale, G, Slavin, S, Goldman, J, Mackinnon, S, Giralt, S, Waldmann, H
Materiálatiipa:	Journal article
Giella:	English
Almmustuhtton:	2002

Geahča maid

In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.
Dahkki: Kottaridis, P, et al.
Almmustuhtton: (2001)

Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype.
Dahkki: Dyer, M, et al.
Almmustuhtton: (1989)

REMISSION INDUCTION IN PATIENTS WITH LYMPHOID MALIGNANCIES USING UNCONJUGATED CAMPATH-1 MONOCLONAL-ANTIBODIES
Dahkki: Dyer, M, et al.
Almmustuhtton: (1990)

In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.
Dahkki: Kottaridis, P, et al.
Almmustuhtton: (2000)

Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up.
Dahkki: Clatworthy, MR, et al.
Almmustuhtton: (2009)

Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?
Dahkki: Chakrabarti, S, et al.
Almmustuhtton: (2004)

Campath 1H (alemtuzumab) in renal transplantation: 5-year comparative follow up.
Dahkki: Watson, C, et al.
Almmustuhtton: (2004)

High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution.
Dahkki: Chakrabarti, S, et al.
Almmustuhtton: (2002)

Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.
Dahkki: Watson, C, et al.
Almmustuhtton: (2005)

Campath-1 Abs 'in the bag' for hematological malignancies: the Cape Town experience.
Dahkki: Novitzky, N, et al.
Almmustuhtton: (2004)

Phase II study of subcutaneous alemtuzumab (Campath-1H) therapy of patients with previously untreated chronic lymphocytic leukemia (CLL).
Dahkki: Lundin, J, et al.
Almmustuhtton: (2001)

CAMPATH-1H in inflammatory arthritis.
Dahkki: Watts, R, et al.
Almmustuhtton: (1993)

TREATMENT OF RHEUMATOID-ARTHRITIS WITH HUMANIZED ANTILYMPHOCYTE ANTIBODY CAMPATH-1H
Dahkki: Watts, R, et al.
Almmustuhtton: (1992)

The effect of treatment with Campath-1H in patients with autoimmune cytopenias.
Dahkki: Willis, F, et al.
Almmustuhtton: (2001)

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).
Dahkki: Lundin, J, et al.
Almmustuhtton: (2002)

CAMPATH: from concept to clinic.
Dahkki: Waldmann, H, et al.
Almmustuhtton: (2005)

Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab.
Dahkki: Avivi, I, et al.
Almmustuhtton: (2004)

A personal history of the CAMPATH-1H antibody.
Dahkki: Waldmann, H
Almmustuhtton: (2002)

Specificity of monoclonal antibody Campath-1.
Dahkki: Hale, G, et al.
Almmustuhtton: (1988)

Campath-1H therapy in refractory ocular inflammatory disease.
Dahkki: Dick, A, et al.
Almmustuhtton: (2000)

CAMPATH-1 MOAB IN THE TREATMENT OF REFRACTORY AUTOIMMUNE THROMBOCYTOPENIC PURPURA (ATP)
Dahkki: Lim, S, et al.
Almmustuhtton: (1993)

Sustained remission of severe resistant autoimmune neutropenia with Campath-1H.
Dahkki: Killick, S, et al.
Almmustuhtton: (1997)

CAMPATH-1 antibodies in stem-cell transplantation.
Dahkki: Hale, G, et al.
Almmustuhtton: (2001)

Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H.
Dahkki: Isaacs, J, et al.
Almmustuhtton: (1996)

Availability of Campath-1 antibodies for bone marrow transplantation.
Dahkki: Hale, G, et al.
Almmustuhtton: (1995)

CAMPATH-1 monoclonal antibodies in bone marrow transplantation.
Dahkki: Hale, G, et al.
Almmustuhtton: (1994)

Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen.
Dahkki: Chakraverty, R, et al.
Almmustuhtton: (2002)

Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases.
Dahkki: Hale, G, et al.
Almmustuhtton: (1994)

In vivo 'purging' of residual disease in CLL with Campath-1H.
Dahkki: Dyer, M, et al.
Almmustuhtton: (1997)

Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality.
Dahkki: Chakrabarti, S, et al.
Almmustuhtton: (2002)

Peripheral blood dendritic cells express CD52 and are depleted in-vivo by treatment with CAMPATH-1H.
Dahkki: Buggins, A, et al.
Almmustuhtton: (2001)

The CAMPATH-1 antigen (CDw52).
Dahkki: Hale, G, et al.
Almmustuhtton: (1990)

Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
Dahkki: Williams, R, et al.
Almmustuhtton: (2000)

T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation.
Dahkki: Hale, G, et al.
Almmustuhtton: (1988)

Inflammation, demyelination, and axonal degeneration: Three aspects of the pathogenesis of multiple sclerosis revealed by campath-1H treatment
Dahkki: Coles, A, et al.
Almmustuhtton: (2003)

Monoclonal antibody therapy of chronic intraocular inflammation using Campath-1H.
Dahkki: Isaacs, J, et al.
Almmustuhtton: (1995)

Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection.
Dahkki: Hale, G, et al.
Almmustuhtton: (1996)

Engraftment of marrow allografts treated with Campath-1 monoclonal antibodies.
Dahkki: Naparstek, E, et al.
Almmustuhtton: (1999)

Requirements for the promotion of allogeneic engraftment by anti-CD154 (anti-CD40L) monoclonal antibody under nonmyeloablative conditions.
Dahkki: Taylor, P, et al.
Almmustuhtton: (2001)

Reconstitution of the Epstein-Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation.
Dahkki: Chakrabarti, S, et al.
Almmustuhtton: (2003)